Addex Therapeutics Ltd (ADXN) Financial Statements

Values in USD · ADR · Reports in CHF

ADXN Financial Data

EBITDA$-7.19M

Revenue (TTM)$188779.63

Gross Profit (TTM)$188779.63

Gross Margin—

Operating Margin-671.94%

ROE-67.24%

ROA-60.94%

Debt/Equity0.00

Current Ratio4.42

FCF$-5.97M

FCF Yield-108.46%

Piotroski F-Score—

Rev/Share (TTM)$0.24

50-Day MA$6.75

200-Day MA$7.97

Shares Outstanding0.00B

ADXN Computed Insights

FCF$-5.97M

FCF Growth Rate—

EPS Growth (CAGR)—

WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

ADXN Financial Statements & Data

Addex Therapeutics Ltd (ADXN) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Addex Therapeutics Ltd's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $188779.63. Gross profit (TTM) is $188779.63. EBITDA is $-7.19M. Earnings per share (EPS) is $0.08. The P/E ratio is -0.71. Market capitalization is $5.51M.

Free cash flow (FCF) is $-5.97M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY18 to FY24. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Addex Therapeutics Ltd's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.